Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria

BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection. Maternal vaccination with RSVpreF (Abrysvo®), which provides transplacental protection, became available in au...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-10-01
Edice:	Frontiers in Public Health
Témata:	nirsevimab RSV newborn RSVpreF vaccine acceptance
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1686581/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!